Россииское кардиологическое общество Российское научное медицинское общество терапевтов Антигипертензивная лига
 Скачать 3.62 Mb.
|
|
1999;96(6):677-80. 54. Petersmarck KA, Teitelbaum HS, Bond JT, Bianchi L, Hoerr SM, Sowers MF. The effect of weight cycling on blood lipids and blood pressure in the Multiple Risk Factor Intervention Trial Special Intervention Group. Int J Obes Relat Metab Disord 1999;23(12):1246-55. 55. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Weight cycling and risk of gallstone disease in men. ArchInternMed 2006;166(21):2369-74. 56. Dennis EA et al. Water Consumption Increases Weight Loss During a Hypocaloric Diet Intervention in Middle ‐aged and Older Adults //Obesity. 2010. Vol. 18. № 2. P. 300–307. 57. Dubnov-Raz G et al. Influence of water drinking on resting energy expenditure in overweight children //International journal of obesity. 2011. Vol. 35. № 10. P. 1295–1300. 58. McTigue KM, Harris R, Hemphill B, Lux L, Sutton S, Bunton AJ, et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;139(11):933-49, I-57. 59. Mäki NE et al. The potential for reducing differences in life expectancy between educational groups in five European countries: the effects of obesity, physical inactivity and smoking // Journal of epidemiology and community health. 2014. С. jech-2013-203501. 60. Ladabaum U et al. Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988 to 2010 // The American journal of medicine. 2014. Vol. 127. № 8. P. 717–727. e12. 61. Physical Activity Guidelines for Americans.U.S. Department of Health and Human Services.http://www.health.gov/PAGuidelines. 07.10.2008 62. Stegenga H et al. Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance //BMJ. 2014. Vol. 349. P. g6608. 137 63. Bray GA, Bouchard C (ed.). Handbook of Obesity: Clinical Applications. CRC Press, 2014. Vol. 2. 64. Seger JC, Horn DB, Westman EC, Primack C, Schmidt SL, Ravasia D, McCarthy W, Ferguson U, Sabowitz BN, Scinta W, Bays HE. Obesity Algorithm, presented by the American Society of Bariatric Physicians, 2014–2015. 65. Hofmann SG et al. The efficacy of cognitive behavioral therapy: a review of meta-analyses //Cognitive therapy and research. 2012. Vol. 36. № 5. P. 427–440. 66. Wadden TA et al. Lifestyle modification for obesity new developments in diet, physical activity, and behavior therapy //Circulation. 2012. Vol. 125. № 9. P. 1157–1170. 67. Weinstein PK. A review of weight loss programs delivered via the Internet. JCardiovascNurs 2006;21(4):251-8. 68. Manzoni GM et al. Internet-based behavioral interventions for obesity: an updated systematic review //Clinical practice and epidemiology in mental health: CP & EMH. 2011. Vol. 7. P. 19. 69. Van Dorsten B, Lindley EM. Cognitive and behavioral approaches in the treatment of obesity //Medical Clinics of North America. 2011. Vol. 95. № 5. P. 971–988. 70. Morgan PJ et al. The ‘Healthy Dads, Healthy Kids’ randomized controlled trial: efficacy of a healthy lifestyle program for overweight fathers and their children //International journal of obesity. 2011. Vol. 35. № 3. P. 436–447. 71. Mozaffarian D et al. Changes in diet and lifestyle and long-term weight gain in women and men //New England Journal of Medicine. 2011. Vol. 364. № 25. P. 2392–2404. 72. Nedeltcheva AV et al. Insufficient sleep undermines dietary efforts to reduce adiposity // Annals of internal medicine. 2010. Vol. 153. № 7. P. 435–441. 73. Khan MH, Victor F, Rao B, Sadick NS (2010) Treatment of cellulite: part II. Advances and controversies. J Am Acad Dermatol 62:373–384 74. Avram M (ed.). Fat Removal: Invasive and Non-invasive Body Contouring. John Wiley & Sons, 2015. 75. Ferrer-Garcia M, Gutiérrez-Maldonado J, Riva G. Virtual reality based treatments in eating disorders and obesity: a review // Journal of Contemporary Psychotherapy. 2013. Vol. 43. № 4. P. 207–221 76. Riva G. The key to unlocking the virtual body: virtual reality in the treatment of obesity and eating disorders //Journal of Diabetes Science and Technology. 2011. Vol. 5. № 2. P. 283–292. 77. Cesa GL et al. Virtual reality for enhancing the cognitive behavioral treatment of obesity with binge eating disorder: randomized controlled study with one-year follow-up // Journal of medical Internet research. 2013. Vol. 15. № 6. 78. Blüher M et al. Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention // Diabetes Care. 2012. Vol. 35. № 2. P. 342– 349. 79. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss //New England Journal of Medicine. 2011. Vol. 365. № 17. P. 1597–1604. 80. Toplak H et al. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs //Obesity facts. 2015. Vol. 8. № 3. P. 166–174. 81. www.obesityalgorothm.org 82. Jensen MD et al. Circulation, 2014;129(25 suppl2):S102-S138 83. Видаль С. Лекарственные препараты в России [Электронный ресурс]. Электрон. дан. Режим доступа: http://vidal. ru. Дата обращения: 2015. 84. Rucker D et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis //Bmj. 2007. 138 85. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review //JAMA. 2014. Vol. 311. № 1. P. 74–86. 86. Torgerson JS et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients // Diabetes care. 2004. Vol. 27. № 1. P. 155–161. 87. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160-167. 88. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G; European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8(1):49-61. 89. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 2001;25(7):1095-1099. 90. Douglas IJ et al. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population ‐based cohort // British journal of clinical pharmacology. 2015. Vol. 79. № 6. P. 1020– 1027. 91. Kim SH et al. Effect of Sibutramine on Weight Loss and Blood Pressure: A Meta ‐ analysis of Controlled Trials //Obesity research. 2003. Vol. 11. № 9. P. 1116– 1123. 92. James WPT et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial //The Lancet. 2000. Vol. 356. № 9248. P. 2119–2125. 93. CatersonI. D et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial //Diabetes, Obesity and Metabolism. 2012. Vol. 14. № 6. P. 523–530. 94. Аметов А. С. Отчет о программе ВЕСНА. Эффективное лечение ожирения – путь борьбы с эпидемией Diabetes mellipidus. // Эффективная фармакотерапия. Эндокринология. Спецвыпуск. 2013; С. 7–11. 7. 95. Мельниченко Г. А., Романцова Т. И., Журавлева М. В. Всероссийская программа безопасного снижения веса «ПримаВера». Итоги первого года проведения // Ожирение и метаболизм. 2014; №1. С. 62–67. 96. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study (vol 37, pg 1443, 2013) //INTERNATIONAL JOURNAL OF OBESITY. 2015. Vol. 39. № 1. P. 187–187. 97. Astrup A et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide //International journal of obesity. 2012. Vol. 36. № 6. P. 843–854. 98. Robinson LE et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis //BMJ open. 2013. Vol. 3. № 1. P. e001986. 99. Bain SC et al. Cardiovascular safety of liraglutide: meta-analysis of major adverse cardiovascular events across weight management and type 2 diabetes development programmes //DIABETOLOGIA. 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER, 2015. Vol. 58. P. S573–S574. 100. Greenway F et al. Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE Obesity and Prediabetes randomized trial // Diabetologie und Stoffwechsel. 2015. Vol. 10. № 04. P. LB6. 139 101. Krempf M et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial // Diabetologia. 233 Spring st, New York, NY 10013 USA: Springer, 2014. Vol. 57. P. S368–S368. 102. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes //New England Journal of Medicine. 2016. Vol. 375. № 4. P. 311–322. 103. Kalra S. Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial //Diabetes Therapy. 2016. P. 1–9. 104. Ryder REJ et al. Liraglutide pancreatitis: The ABCD nationwide liraglutide audit //The British Journal of Diabetes & Vascular Disease. 2013. Vol. 13. № 5–6. P. 253–259. 105. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer // Diabetes research and clinical practice. 2012. Vol. 98. № 2. P. 271–284. 106. Fried M et al. Interdisciplinary European guidelines on metabolic and bariatric surgery // Obesity surgery. 2014. Vol. 24. № 1. P. 42–55. 107. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Obes Surg 2007; 17: 260-70 108. American association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic and non-surgical support of the bariatric surgery patient. Surg Obes Relat Dis 2008; 4(5 Suppl): S109-84. 109. National Institute for Clinical Excellence: 2002 Guidance on the use of surgery to aid weight reduction for people with morbid obesity (Technology Appraisal No 46). National Institute for Clinical Excellence, London, 2002. 110. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2013. 111. Nainggolan L. New obesity guidelines: authoritative 'roadmap' to treatment. Medscape Medical News. November 12, 2013. 112. Ravussin E. et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy // Obesity. 2009. Vol. 17. № 9. P. 1736-1743. 113. Sugerman HJ et al. Gastric bypass for treating severe obesity // The American journal of clinical nutrition. 1992. Vol. 55. № 2. P. 560S–566S. 114. Sugerman HJ. Effects of increased intra-abdominal pressure in severe obesity //Surgical Clinics of North America. 2001. Vol. 81. № 5. P. 1063–1075. 115. Sugerman H. J. 2 Pathophysiology of Obesity Comorbidity: The Effects of Chronically Increased Intra-abdominal Pressure //Minimally Invasive Bariatric Surgery. Springer New York, 2015. P. 7–13. 116. Cohen P. G. Abdominal obesity and intra-abdominal pressure: a new paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection // Hormone molecular biology and clinical investigation. 2012. Vol. 11. № 1. P. 317–320. 117. Jensen MD et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults // Circulation. 2013. Vol. 129. P. S102–S138. 118. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. ObesSurg 2007; 17: 260-70 140 119. Sauerland S et al. Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES) // Surgical Endoscopy and Other Interventional Techniques. 2005. Vol. 19. № 2. P. 200–221. 120. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011 //Obesity surgery. 2013. Vol. 23. № 4. P. 427–436. 121. Ionut V et al. Gastrointestinal hormones and bariatric surgery ‐induced weight loss //Obesity. 2013. Vol. 21. № 6. P. 1093–1103. 122. Inge TH et al. Perioperative outcomes of adolescents undergoing bariatric surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study // JAMA pediatrics. 2014. Vol. 168. № 1. P. 47–53. 123. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium et al. Peri-operative safety in the longitudinal assessment of bariatric surgery // The New England journal of medicine. 2009. Vol. 361. № 5. P. 445. 124. Isono S. Obstructive sleep apnea of obese adults. Anesthesiology. 2009;110:908–921. 125. Horner RL. Contributions of passive mechanical loads and active neuromuscular compensation to upper airway collapsibility during sleep. J Appl Phsiol. 2007;102:510–512. 126. Tagaito Y, Isono S, Remmers JE, Tanaka A, Nishino T. Lung volume and collapsibility of the passive pharynx in patients with sleep-disordered breathing. J Appl Phsiol. 2007;103:1379–1385. 127. Heinzer R, White DP, Malhotra A et al. Effect of increased lung volume on sleep disordered breathing in patients with sleep apnea. Thorax. 2006;61:435- 439. 128. Malhotra A, Hillman D. Obesity and the lung: 3. Obesity, respiration and intensive care. Thorax. 2008;63:925–931. 129. Sato M, Suzuki M, Suzuki J et al. Overweight patients with severe sleep apnea experience deeper oxygen desaturation at apnoeic events. JMedDentSci. 2008;55:43-47. 130. Magnusson L, Spahn DR. New concepts of atelectasis during general anaesthesia. Br J Anaesth. 2003;91:61–72. 131. ASA Task Force on Perioperative Management of Patients with OSA. Practise guidelines for the perioperative management of patients with obstructive sleep apnea. Anesthesiology. 2006;104:1081–1093. 132. Leone N, Courbon D, Thomas F et al. Lung function impairment and metabolic syndrome. The critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179:509–516. 133. Candiotti K, Sharma S, Shankar R. Obesity, obstructive sleep apnea, and diabetes mellitus: anaesthetic implications. Br J Anaesth. 2009;103 (Suppl 1):i23– i30. 134. Joris JL, Sottiaux TM, Chiche JD, Desaive CJ, Lamy ML. Effect of bi- level positive airway pressure (BiPAP) nasal ventilation on the postoperative pulmonary restrictive syndrome in obese patients undergoing gastroplasty. Chest. 1997;111:665–670. 135. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой (7-й вып.) // Сахарный диабет. 2015. Т. 18. № 1S. 136. Дедов И. И., Шестакова М. В., Аметов А. С., Анциферов М. Б., Галстян Г. Р., Майоров А. Ю., Мкртумян А. М., Петунина Н. А., Сухарева О. Ю. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2-го типа: обновление консенсуса совета экспертов 141 Российской ассоциации эндокринологов (2015 г.) // Сахарный диабет. 2015. № 1. С. 4–22. 137. Basile J. N. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM) //Journal of Diabetes and its Complications. 2013. Vol. 27. №. 3. P. 280–286. 138. Graham GG et al. Clinical pharmacokinetics of metformin // Clinical pharmacokinetics. 2011. Vol. 50. № 2. P. 81–98. 139. UK Prospective Diabetes Study (UKPDS) Group et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) //The Lancet. 1998. Vol. 352. № 9131. P. 854– 865. 140. Bailey CJ, Turner RC. Metformin //New England Journal of Medicine. 1996. Vol. 334. № 9. P. 574–579. 141. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update // Annals of internal medicine. 2002. Vol. 137. № 1. P. 25–33. 142. Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis // Archives of internal medicine. 2003. Vol. 163. № 21. P. 2594–2602. 143. Scheen AJ. New therapeutic approaches in type 2 diabetes // Acta Clinica Belgica. 2014. 144. Aroda VR et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review //Clinical therapeutics. 2012. Vol. 34. № 6. P. 1247–1258. e22. 145. United States Food and Drug Administration. FDA briefing document: NDA 202293 dapagliflozin tablets, 5 and 10 mg sponsor: Bristol-Myers Squibb. URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria ls/drugs/ndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf 146. Macdonald FR, Peel JE, Jones HB et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010;12:1004–12. 147. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. DiabetesObesMetab 2010;12:510–16 148. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012;32(1):80–94. 149. Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes // New England Journal of Medicine. 2015. Vol. 373. № 22. P. |